All News
Phys.org / No cities on the moon—there isn't enough water, scientists say
The discovery of water in dark craters at the moon's poles has sparked a "moon rush" to establish bases there, followed by villages, cities and heavy industry. How sustainable is this rush?
Phys.org / Luminescence dating pushes age of South Dakota's Mammoth Site back by more than 100,000 years
Deep within an ancient sinkhole lie the remains of dozens of mammoths, prehistoric wanderers who waded into the warm springs to their deaths. These deaths had long been accepted as having occurred roughly 26,000 years ago, ...
Medical Xpress / Drug decriminalization in BC reduced police encounters for drug possession, with no changes in drug-related deaths
British Columbia's drug decriminalization policy was associated with a substantial decrease in police encounters for drug possession, while neither decriminalization nor the subsequent partial recriminalization was associated ...
Phys.org / Gravitational-wave analysis narrows the search for black hole impostors
Black holes are regions of spacetime where gravity is so strong that nothing, not even light, can escape. When two black holes orbit each other and merge, they produce gravitational waves (i.e., ripples in spacetime) that ...
Medical Xpress / New US Medicare pricing policies could reshape global pharmaceutical markets
A new modeling study published in The Lancet suggests that U.S. Medicare's new "Most-Favored-Nation" pricing policy, which ties what Medicare pays for medicines to prices charged in other high-income countries, could push ...
Medical Xpress / Zidesamtinib demonstrates 93% response rate in ROS1-positive lung cancer
New results from the global phase 1/2 ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received ...
Medical Xpress / Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation
Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients ...
Medical Xpress / Update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated lung cancer
An exploratory 8-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB–IIIA ...
Medical Xpress / First-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant lung cancer
First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small ...
Medical Xpress / Masked antibodies may open intracellular treatment route for Parkinson's disease
Over the past few decades, antibody-based therapies have revolutionized modern medicine and are now widely used to treat cancer, autoimmune diseases, inflammatory disorders and even infectious diseases. Despite their success, ...
Phys.org / AI helps microscopes find the most informative nanoscale features in a sample
Researchers at the Department of Energy's Oak Ridge National Laboratory (ORNL) have developed an artificial intelligence framework that helps researchers use atomic force microscopes to identify important nanoscale features ...
Phys.org / Consumers demand transparency, but is it rewarded?
Transparent supply chains boost consumer trust—if the results are positive. But what if they aren't? A new paper by Kühne Logistics University (KLU), in collaboration with the University of Tennessee and Tilburg University, ...
